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Summary: In most studies, concentrations of a2-macroglobulin are determined by immunological techniques.
In this study, the amidolytic activity of porcine pancreatic elastase complexed with a2-macroglobulin was
measured using an elastase-specific Substrate, succinyl-trialanyl-p-nitroanilide. The activities of plasmas from
47 emphysema cases were compared with 39 normal subjects. The age ranges of both groups were from 50
to 84 years. The mean activity of bound elastase in emphysema cases was 2.48 + 0.03 kU/1 of plasma. The
mean for normal subjects was 1.48 ± 0.11 kU/1 of plasma. The difference was very significant (2P < 0.001).
All except 2 of the emphysema cases had smoked. The same results were obtained when only people who
had smoked for 25 years or more were included in the analysis. All the plasma samples of people included in
the study were assayed by an immunological method for absolute level (in g/l) of arproteinase inhibitor. The
levels of arproteinase inhibitor for all the persons studied feil within the normal ränge for MM-phenotypes
(2to4g/l).
Introduction
Much work has been done on the elastase-inhibiting
capacity of plasma. Attempts have been made to
relate this to development of hing disease (1). The
main elastase inhibitor in plasma is ai-proteinase in-
hibitor. This inhibitor has been extensively studied
and the relationship between aj-proteinase inhibitor
deficiency and development of emphysema, äs origi-
nally suggested by Laurell & Eriksson (2), is well
docuinented. However, since most emphysema cases
have normal levels of -proteinäse inhibitor (3), there
must be other factors responsible for the development
of this disease* in addition to the Variation in eoncen-
trations of arproteinase inhibiior.
Smoking is one factor which is higfaly corfelated to
the development of emphysema (4, 5). However, not
all smokers develop emphysema. Nön-smokers with
the ZZ phenotype for -proteinase inhibitor, do not
.all develop the disease either. This leads to the con-
clusion that the disease is multifactorial.
A second elastase-binding factor, present in plasma,
is a2-xnacroglobulin. This has been classified äs an
elastase-inhibitor because it reduces the elastolytic
activity of elastase against native elastin. However, i t
does not prevent attack on lower molecular weight
Substrates, such äs succinyl-trialanyl-p-nitroanilide.
Tropoelastin, a precursor of elastin, is also attacked
by the complex of a2-macroglobulin with elastase at
about 19 times the rate of attack on native elastin
(6), but according to Keuppers et al. (7), only frag-
ments of relative molecular size MT < 10000 are
hydrolysed by the complex. The rate constants of the
reactions are also dependent on the type of elastase
under consideration. When porcine pancreatic elas-
tase is complexed with human a2-macroglobulin, the
activity against succinyl-trialanyl-/?-nitroanilide drops
to 74% of that of the unbound porcine pancreatic
elastase. On the other hand, human neutrophil elas-
tase when bound to a2-macroglobulin, is 15 times äs
active äs the unbound neutrophil elastase (8).
A further consideration is the modulating eflect of
a2-macroglobulin on the Inhibition of elastase by ar
proteinase inhibitor, when mixtures of a2-macroglob-
ulin and arproteinase inhibitor react with porcine
pancreatic elastase. We have used this property to
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devise a method for measurement of the elastase-
binding capacity of a2-macroglobulin and ai-protein-
ase Inhibitor in plasma, using porcine pancreatic elas-
tase (9).
The present communication shows that the elastase-
binding capacity of a2-macroglobulin is highly cor-
related to the development of emphysema.
Materials and Methods
Human arproteinase inhibitor was obtained from Hoechst.
Porcine pancreatic elastase was obtained from Boehringer,
Mannheim. The Substrate used for porcine pancreatic elastase
was succinyl-trialanyl-/?-nitroanilide from Hoechst.
Tris(hydroxymethyl)aminomethane buffer and all other re-
agents were of analytical grade (Merck).
Subjects
Fresh human blood was drawn into a Venoject tube containing
lithium heparin (Comopharm, Johannesburg). Patients and
controls were in the age group 50 to 84 years. Fofty-seven
caucasian outpatients with severe chronic obstructive pulmo-
nary disease and emphysema, s defmed by criteria in the
literature (10), and according to the physician's best diagnosis,
were selected from the Respiratory Clinic of the J. G. Strydom
Hospital in Johannesburg. The 39 controls were caucasian
volunteers donating blood to the South African Blood Trans-
fusion Service. All subjects had given informed consent for the
taking of their blood for this study. Smoking history was
recorded for all subjects.
Assay of activity of the complex between plasma a2-
macroglobulin and porcine pancreatic elastase
The theoretical aspects of this assay have been discussed in a
previous paper and a comparison has been made with other
published methods (9). Since the complex is active against
succinyl-trialanyl-/?-nitroanilide in the presence of excess otr
proteinase inhibitor, the plasma was first allowed to react with
excess porcine pancreatic elastase and then the residual un-
bound porcine pancreatic elastase was neutralized with ar
proteinase inhibitor. For both reactions 99% of the binding is
completed within 2min (unpublished observations). Ten mi-
croliters of plasma were reacted at 37 °C for 5 min with 100 μg
porcine pancreatic elastase in 3.5 ml of 0.1 mol/1
Tris(hydroxymethyl)aminomethane-HCi buffer, pH 7.4. The ex-
cess porcine pancreatic elastase was then completely inhibited
by addition of 250 μg of α,-proteinase inhibitor in 100 μΐ of
buffer s above. After binding of α,-proteinase inhibitor at
37 °C for 5 min the assay was started by addition of 2 mg of
succinyl-trialanyl-/?-nitroanilide in 50 μΐ of buffer.
The temperature was maintained at 37 °C for a further 15 min
and the hydrolysis then stopped by addition of 0.5 ml of 100 g/l
citric acid solution. Absorbance was read at 410 nm. The
activity of the porcine pancreatic elastase-plasma-a2-macro-
globulin complex was calculated in International Enzyme Units
using the value for the molar lineic absorbance forp-nitroaniline
of 960 m2/mol.
Freezing and thawing does not affect elastase-binding capacity,
but even when frozen, the capacity decreases slowly. This is in
agreement with the work of Gressner & Peltzer (11) who found
that it was possible to assay the trypsin-binding capacity of a2-
macroglobulin only up to 10 days if stored at 4 °C and up to
3 weeks if stored at —20 °C. To avoid any possible inactivation,
this assay was always performed within 24 hours after blood
collection.
The active site of porcine pancreatic elastase is not the same s
the site to which a2-macroglobulin binds. Therefore, one would
expect that porcine pancreatic elastase which has lost elastolytic
activity could still bind to a2-macroglobulm. Hence,; we used
the same batch of porcine pancreatic elastase throughout for
the assays and assayed the normals and patients in altemate
batches of 9 to 12 to eliminate possible bias. Zero time blanks
and elastase activity assays, without addition of plasma or ar
proteinase inhibitor, were also performed each time. There was
no loss of amidolytic activity of our batch of porcine pancreatic
elastase over the period of the study. With the batch of porcine
pancreatic elastase which we used, the amidolytic activity on
succinyl-trialanyl-/j-nitroanilide was determined in exactly the
same way s the other assay described above, except that plasma
and cti-proteinase inhibitor were replaced with 110 μΐ water,
and the incubation period with succinyl-trialanylr/^nitroanilide
before adding the citric acid was 2 min. In addition, the endog-
enous elastase activity was tested by running the whole assay
without the addition of elastase.
Absolute assay of ai-proteinase inhibitor
The absolute concentration of arproteinase inhibitor was de-
termined by an antibody precipitation, laserrnephelometric
method (12). The monospecific antisera were obtained from
Dako, Denmark. The Standard used for ai-proteinase inhibitor
was 'Protein Standard, Plasma' from Behring, West Germany.
Effect of bronchodilators on binding activity of a2-
macroglobulin
In order to ascertain whether bronchodilators, which are often
used by patients with emphysema and chronic obstructive lung
disease, had any effect on the binding activity of a2-macroglob-
ulin, a study was perfonned on a volunteer. The binding activity
of the subject's plasma was assayed before administration of
two drugs and again after treatment. The regimen c.onsisted of
treatment 3 times a day with two puffs of fenoterol hydrobro-
mide (Berotec®, Boehringer Ingefheim) over a period of 10
weeks. During the final week, 15 ml of Solphyllex® (theophyl-
line 100 mg, etofylline 10 mg, diphenylpyraline HC1 8mg,
ammonium chloride 720 mg, Na-citrate 300 mg, ethanol (vol-
ume fraction 0.2), Chloroform (volume fraction 0.002)) were
taken 3 times daily after meals and also at bedtime.
Statistical evaluation
Four different criteria viz. sex, smoking, age, and state of health,
were statistically evaluated using Student's t-test for 2 different
variables viz. absolute level of arproteinase inhibitor and the
measured elastase-binding capacity of a2-macroglobulin in the
plasma. The coefficient of Variation of the method for repeti-
tions on the same sample was 2.9%, while day to day Variation
on the same sample was 3.2%.
Results
Absolute ctj-proteinase inhibitor concentra·
tions
There was no significant differeiice between healthy
smokers and non-smokers or between those with em-
physema, and healthy controls in the age group from
» i
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50 to 84 years. Females had slightly higher concen-
trations than maJes, which was significant in controls
(2P < 0.05) but not in the patients (2P < 0.6). There
was no correlation with age for the group from 50 to
84 years (linear correlation coefficient (r) = 0.108)
(tab. 2).
Endogenous elastase activity
No residual endogenous amidolytic activity was pres-
ent in any of the plasma samples.
Elastase-binding capacity of a2-macro-
globulin
Smoking made no difference to the binding activity.
There was no correlation of binding activity with age
in the age group from 50 to 84 years (r = 0.149 for
controls and r = 0.065 for emphysema cases). There
was no difference between males and females in the
controls for the age group from 50 to 84 years (2P
> 0.6) (tab. 1). The emphysema cases, however,
showed a definite difference between the sexes (tab.
2), (2P < 0.005).
Comparison of emphysema cases with controls gave
the results shown in figure 1. It is clear that elastase-
binding capacity levels of the healthy subjects are
much lower than those of emphysema patients. The
calculated mean for 39 subjects who did not have
emphysema (controls) was 1.48 (Standard error
= 0.08) kU/1 plasma; that for the 47 emphysema
patients was 2.48 kU/1 plasma (Standard error
= 0.10). A Student t-test on the two groups gave
t = 7.6059 with 84 degrees of freedom (P < 0.001).
This is conciusive evidence that the two groups are
different.
From figure l we can also conclude the follqwing:
(i) None of the healthy smokers or ex-smokers has a
porcine pancreatic elastase-binding capacity for the
a2-macroglpbulin in their plasma, above 2.18 kU/1.
(ii) All except one of the healthy non-smokers had a
porciiie pancreatic elastase-binding capacity föf the
a2-macroglobujin in their plasgaa, of less than 2.18
kU/1. The one with a level of 2.61 kU/1 shows no sign
of emphysema at age 61. He is known to have been
exposed to a minimum level of side-stream smoke.
(iii) Most of the emphysema cases have a level of
porcine pancreatic elastase-binding capacity for the
a2-niacroglobulin in their plasmas, above 2.18 kU/1.
There are, however, several cases with lower levels,
one äs low äs 1.6 kU/1. All the emphysema patients
had been heavy smokers for many years.
Tab. 1. Normal healthy volunteers from 50 to 84 years of age.
Values of arproteinase Inhibitor and eiastase-binding






































a Number of subjects used.
b Mean value in plasma ± Standard error.
c kU/1 = kilo-international units of elastase (amidolytic) acti-
vity per liter of plasma.
d Group difference significant at 2P < 0.05.
e Ex-smokers excluded. Smokers 25 years or more compared
with those who never smoked except for side-stream smoke.
f NC = no linear correlation.
Tab. 2. Emphysema patients from 50 to 84 years of age. Values
of arproteinase inhibitor and elastase-binding capacity
































a Number of subjects used.
b Mean value in plasma ± Standard error.
c kU/1 = kilo-international units of elastase (amidolytic) acti-
vity per liter of plasma.
d Group difference significant at 2P < 0.005.
e Smoked for 25 years or more compared with those who
stopped smoking before they had smoked for 25 years or
never smoked at all except for side-stream smoke.
f NC = no linear correlation.
Effect of bronchodilators on elastase-bind-
ing capacity of a2-macroglobulin
The regimen described had no significant effect on
the elastase-binding capacity of a2-macroglobulin in
the volunteer (before treatment 2.61 kU/1 of plasma,
and after treatment 2.44 kU/1 of plasma).
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Fig. 1. Elastase-binding capacity of a2-macroglobulin in
plasma:
(a) 30 healthy smokers;
(b) 15 healthy non-smokers;
(c) 47 patients with chronic obstructive lung disease.
All three groups were from 50 to 84 years of age.
Discussion
Emphysema has a multifactorial aetiology. Smoking
is strongly linked to the development of this disease.
When cigarette smoke gets into the lung, it triggers a
series of celhilar and molecular events. The alveolar
macrophages release a chemotactic factor which at-
tracts polymorphonuclear leukocytes (13). Further^
more, this chemotactic factor acts on the neutrophils
to release their granulär contents, including elastase
which is responsible for the destraction of elastin (14).
The main inhibitor of elastase is a^proteinase inhib-
itor. Since 1963, when Laurell & Eriksson (2) dem-
onstrated the presence of different phenotypes of at-
proteinase inhibitor, much attention has been devoted
to the study of aj-proteinase inhibitor deficiencies in
relation to the incidence of emphysema. However,
those studies have revealed that the majority of em-
physema patients have normal plasma concentrations
of dj-proteinase inhibitor (15).
It has been suggested that cigarette smoke inactivates
-proteinase inhibitor in the lung, by oxidizing the
critical methionyl residues. This mechanism was con-
firmed by the findings of Carp et al. (16). This oxi-
dative inactivation is not necessarily permanent, äs it
can be reversed by the enzyme methionine sulphoxide-
peptide reductase (17). At present there is considerable
controversy äs to whether or not smoking inactivates
a^proteinase inhibitor. Recent studies were unable to
show any difference in the functional activity of (Xi-
proteinase inhibitor from bronchoalveolar lavage, be*
tween smokers and nön-smokers (18,19). Also, smok-
ing does not affect (Xi-proteinase inhibitor activity in
serum, äs demonstrated by Bridges et al. (20).
Oür results show that the plasma concentrations of
di^proteinase inhibitor in all emphysema cases were
in the normal ränge, and no difference was found
between healthy controls and our patients (P > 0.4).
However the plasma concentrations of a^-macro-
globulin äs expressed by elastase-binding capacity
were significantly different in emphysema patients
from those of healthy controls.
Pedersen & Franck (21), using the rocket immuno-
electrophoresis technique for measuring a2-macro-
globulin plasma concentrations, also detected a signifi-
cant difference between 20 patients with chronic air-
ways obstrüction and 20 age- and sex-matched con-
trols. Using the same technique, however, other in-
vestigators found no difference between these two
groups (22, 23, 24).
Since all except two of the emphysema cases were
active smokers or were ex-smokers, and the two nonr
smokers had both been exposed to constänt side-
stream smoke from their spouses and work colleagues,
a comparison was made between those who had
smoked for at least 25 years in the two groups. Here
the mean value of elastase-binding capacity pf healthy
long-term smokers (n == 11) was 1.33 kU/1 of plasma
while the mean value of elastase-binding capacity for
the long-term smoking emphysema patients (n = 39)
was 2.45 kU/1 of plasma (2P < 0.001). From this we
deduce that the difference in the concentrations is not
due to smoking; some healthy non-srnokers had even
higher concentrations than the average of the healthy
smokers. Since neither age nor smoking are the cause
of high concentrations of elastase-binding capacity of
a2-macroglobulin in plasma, and because the emphy-
sema cases have high values of this capacity^ we pos^
tulate that a high elastase-binding capacity of a2-
macroglobulin in plasma, in cojntpnctiöri with a
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chronic hing challenge such äs smoking, is a predis-
posing factor for the development of emphysema. A
possible mechanism for this is that since the bound
elastase is not inhibited by arproteinase Inhibitor, it
can still cause proteolysis of elastin-precursors (6).
This prevents the replacement of any elastin which is
destroyed by the normal turnover mechanism in the
body, resulting in a gradual depletion of elastin, which
leads to emphysema. Tobacco smoke is known to
inhibit ciliary action and it is possible that it also
inhibits the phagocytosis of the complex between a2-
macroglobulin and neutrophil elastase to a sufficient
extent to allow the complex to exert its proteolytic
effect on elastin-precursors in the lung.
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